Compare MHD & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MHD | IRWD |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 609.5M | 520.6M |
| IPO Year | N/A | 2010 |
| Metric | MHD | IRWD |
|---|---|---|
| Price | $11.86 | $4.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.12 |
| AVG Volume (30 Days) | 124.9K | ★ 7.2M |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 4.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | N/A | ★ $338,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.01 |
| P/E Ratio | ★ N/A | $22.47 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.92 | $0.53 |
| 52 Week High | $12.18 | $5.78 |
| Indicator | MHD | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 63.07 | 60.33 |
| Support Level | $11.62 | $3.11 |
| Resistance Level | $11.77 | $5.78 |
| Average True Range (ATR) | 0.09 | 0.34 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 93.94 | 33.89 |
Blackrock Muniholdings Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income taxes. The fund mainly invests its managed assets in municipal bonds rated investment grade or, if unrated, are deemed to be of comparable quality by the investment adviser at the time of investment. Its investment portfolio is mainly comprised of long-term municipal bonds with a maturity of more than ten years at the time of investment. The fund can also invest directly in such securities or synthetically through the use of derivatives.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.